Evidence map›Paper›PMID 42427479›Full record

ArticleMediastinum (Hong Kong, China)2026

A real-world cohort study comparing chemotherapy and surgery in the treatment of stage IVA thymomas with pleural dissemination.

Xuefei Zhang, Changlu Wang, Zhitao Gu, Qin Zhang, Lanting Gao, Xiuxiu Hao, Fenghao Yu, Ning Xu, Yan Shen, Lei Zhu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mediastinum (Hong Kong, China), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xuefei Zhang *Department of Thoracic Surgery, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Changlu Wang *Department of Radiation Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Zhitao GuDepartment of Thoracic Surgery, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Qin ZhangDepartment of Radiation Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Lanting GaoDepartment of Radiation Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xiuxiu HaoDepartment of Thoracic Surgery, Shanghai East Hospital, Tongji University Medical School, Shanghai, China.
Fenghao YuDepartment of Thoracic Surgery, Shanghai East Hospital, Tongji University Medical School, Shanghai, China.
Ning XuDepartment of Thoracic Surgery, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yan ShenDepartment of Radiology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Lei ZhuDepartment of Pathology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xiaolong FuDepartment of Radiation Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Teng MaoDepartment of Thoracic Surgery, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Wentao FangDepartment of Thoracic Surgery, Shanghai East Hospital, Tongji University Medical School, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chemotherapy is the guideline-recommended first-line therapy for stage IVA thymomas (TMs) with pleural dissemination, but its efficacy has never been specifically assessed. We aim to evaluate the efficacy of chemotherapy, and to compare the results of surgery and chemotherapy without surgery in these patients. Methods: This is a real-world retrospective study. Consecutive patients with stage IVA TM with pleural dissemination who received chemotherapy or upfront surgery between 2007 and 2018 were enrolled. Propensity-score matching (PSM) was used to balance selection bias between groups. Objective response rate (ORR) in pleural lesions to chemotherapy and long-term outcomes including disease-control time (DCT), progression-free survival (PFS) and overall survival (OS) were assessed between groups. Results: Altogether 168 patients with stage IVA TM with pleural dissemination were enrolled. In 124 patients who received chemotherapy as the first-line treatment, ORR was only 6.5% with no complete remission observed, with 7.3% progression diseases. After PSM, surgery was associated with better prognosis than no-surgery [median DCT: 39.0 Conclusions: Chemotherapy as the first-line treatment is far from satisfactory for stage IVA TMs with pleural dissemination and may not be appropriate as a routine recommendation. Surgery plays a more important role as an alternative option.

Indexed as

chemotherapypleural disseminationsurgeryThymoma (TMs)

Identifiers

PMID42427479
PMCPMC13346007

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.